Role of cancer-associated fibroblasts in oral squamous cell carcinomas, surgical margins, and verrucous carcinomas: An immunohistochemical study
Background and Aim: Cancer-associated fibroblasts (CAFs) are among the key tumor microenvironment components that determine tumor invasion, progression, and resistance to cancer therapeutics. Histologically normal mucosa adjacent to oral squamous cell carcinoma (OSCC) has been shown to harbor CAFs which aid in the loco-regional recurrence of the lesion. Verrucous carcinoma (VC), a low-grade variant of squamous cell carcinoma, has a better clinical outcome. However, few VCs show an aggressive biological course and necessitate wide excision with strict follow-up. Scarce literature is available regarding the role of CAFs in VCs. Thus, our study aimed to
evaluate the frequency of CAFs in OSCC, normal mucosa adjacent to OSCC, and VC.
Methods: Thirty cases of squamous cell carcinoma, normal mucosa adjacent to OSCC, and VC each were included in the study. The sections were stained with an antibody against alpha-smooth muscle actin protein and CAF frequency was evaluated.
Results: The CAF frequency was highest in squamous cell carcinoma, followed by VC, and least in normal mucosa adjacent to OSCC (P<0.001).
Conclusion: CAF frequency progressively increases with an increase in the grade or biological behavior of the lesion. Thus, screening CAF frequency in these benign and malignant oral lesions is necessary for better treatment outcomes.
Relevance for Patients: The immunohistochemical screening for CAFs in OSCC and VC can serve as an integrated approach for the development of a directed treatment plan that leads to a better patient prognosis. Routine assessment of CAF frequency in surgical margins can serve as an adjunct in determining clear margins and possible locoregional recurrence. Furthermore, target therapy for CAFs can be used to minimize possible recurrence and distant metastasis.
[1] Custódio M, Biddle A, Tavassoli M. Portrait of a CAF: The Story of Cancer-Associated Fibroblasts in Head and Neck Cancer. Oral Oncol 2020;110:104972.
[2] Joshi RS, Kanugula SS, Sudhir S, Pereira MP, Jain S, Aghi MK. The Role of Cancer-Associated Fibroblasts in
Tumor Progression. Cancers (Basel) 2021;13:1399.
[3] Chen X, Song E. Turning Foes to Friends: Targeting Cancer-Associated Fibroblasts. Nat Rev Drug Discov
2019;18:99-115.
[4] Dourado MR, Guerra EN, Salo T, Lambert DW, Coletta RD. Prognostic Value of the Immunohistochemical
Detection of Cancer-Associated Fibroblasts in Oral Cancer: A Systematic Review and Meta-Analysis. J Oral
Pathol Med 2018;47:443-53.
[5] Knops AM, South A, Rodeck U, Martinez-Outschoorn U, Harshyne LA, Johnson J, et al. Cancer-Associated
Fibroblast Density, Prognostic Characteristics, and Recurrence in Head and Neck Squamous Cell Carcinoma:
A Meta-Analysis. Front Oncol 2020;10:565306.
[6] D’Arcangelo E, Wu NC, Cadavid JL, McGuigan AP. The Life Cycle of Cancer-Associated Fibroblasts within the
Tumour Stroma and its Importance in Disease Outcome. Br J Cancer 2020;122:931-42.
[7] Santi A, Kugeratski FG, Zanivan S. Cancer Associated Fibroblasts: The Architects of Stroma Remodeling.
Proteomics 2018;18:e1700167.
[8] Denton AE, Roberts EW, Fearon DT. Stromal Cells in the Tumor Microenvironment. Adv Exp Med Biol
2018;1060:99-114.
[9] Gascard P, Tlsty TD. Carcinoma-associated Fibroblasts: Orchestrating the Composition of Malignancy. Genes Dev 2016;30:1002-19.
[10] Neophytou CM, Panagi M, Stylianopoulos T, Papageorgis P. The Role of Tumor Microenvironment
in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities. Cancers (Basel) 2021;13:2053.
[11] Yoshida GJ, Azuma A, Miura Y, Orimo A. Activated Fibroblast Program Orchestrates Tumor Initiation and
Progression; Molecular Mechanisms and the Associated Therapeutic Strategies. Int J Mol Sci 2019;20:2256.
[12] Mezawa Y, Orimo A. The Roles of Tumor and Metastasispromoting Carcinoma-associated Fibroblasts in Human Carcinomas. Cell Tissue Res 2016;365:675-89.
[13] Lin NN, Wang P, Zhao D, Zhang FJ, Yang K, Chen R. Significance of Oral Cancer-associated Fibroblasts in
Angiogenesis, Lymphangiogenesis, and Tumor Invasion in Oral Squamous Cell Carcinoma. J Oral Pathol Med
2017;46:21-30.
[14] Kellermann MG, Sobral LM, da Silva SD, Zecchin KG, Graner E, Lopes MA, et al. Myofibroblasts in the Stroma of Oral Squamous Cell Carcinoma are Associated with Poor Prognosis. Histopathology 2007;51:849-53.
[15] Vered M, Dobriyan A, Dayan D, Yahalom R, Talmi YP, Bedrin L, et al. Tumor-host Histopathologic Variables,
Stromal Myofibroblasts and Risk Score, are Significantly Associated with Recurrent Disease in Tongue Cancer.
Cancer Sci 2010;101:274-80.
[16] Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-β-Associated Extracellular Matrix Genes Link Cancer-Associated Fibroblasts to Immune Evasion and Immunotherapy Failure. Nat Commun 2018;9:4692.
[17] Angadi PV, Patil PV, Kale AD, Hallikerimath S, Babji D. Myofibroblast Presence in Apparently Normal Mucosa Adjacent to Oral Squamous Cell Carcinoma Associated with Chronic Tobacco/Areca Nut Use: Evidence for Field Cancerization. Acta Odontol Scand 2014;72:502-8.
[18] Chaudhary M, Gadbail AR, Vidhale G, Gadbail MP, Gondivkar SM, Gawande M, et al. Comparison of Myofibroblasts Expression in Oral Squamous Cell Carcinoma, Verrucous Carcinoma, High Risk Epithelial Dysplasia, Low Risk Epithelial Dysplasia and Normal Oral Mucosa. Head Neck Pathol 2012;6:305-13.
[19] Smitha A, Rao K, Umadevi HS, Smitha T, Sheethal HS, Vidya MA. Immunohistochemical Study of α-Smooth Muscle Actin Expression in Oral Leukoplakia and Oral Squamous Cell Carcinoma. J Oral Maxillofac Pathol 2019;23:59-64.
[20] Seifi S, Shafaei S, Shafigh E, Sahabi SM, Ghasemi H. Myofibroblasts Stromal Presence and Distribution in
Squamous Epithelial Carcinomas, Oral Dysplasia and Hyperkeratosis. Asian Pac J Cancer Prev 2010; 11: 359-64.
[21] Johnson N, Franceschi S, Ferlay J, Ramadas K, Schmid S, MacDonald DG, et al., editors. Pathology and Genetics of Tumours of the Head and Neck. In: World Health Organization Classification of Tumours. Vol. 9. Lyon, France: IARC Press; 2005. p. 166-75.
[22] Angadi PV, Krishnapillai R. Cyclin D1 Expression in Oral Squamous Cell Carcinoma and Verrucous Carcinoma: Correlation with Histological Differentiation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103:e30-5.
[23] Harishankar MK, Mohan AM, Krishnan AV, Devi A. Downregulation of Notch4 a Prognostic Marker in Distinguishing Oral Verrucous Carcinoma from Oral Squamous Cell Carcinoma. Braz J Otorhinolaryngol
2019;85:11-16.
[24] Laxmidevi LB, Angadi PV, Pillai RK, Chandreshekar C. Aberrant β-catenin Expression in the Histologic Differentiation of Oral Squamous Cell Carcinoma and Verrucous Carcinoma: An Immunohistochemical Study.
J Oral Sci 2010;52:633-40.
[25] Niranjan KC, Sarathy NA, Alrani D. MCM-2 Expression Differentiates Potentially Malignant Verrucous Lesions from Oral Carcinomas. Ann Diagn Pathol 2018;34:72-6.
[26] Hosseinpour S, Mashhadiabbas F, Ahsaie MG. Diagnostic Biomarkers in Oral Verrucous Carcinoma: A Systematic Review. Pathol Oncol Res 2017;23:19-32.
[27] Anderson M, Muro-Cacho C, Cordero J, Livingston S, Muñoz-Antonia T. Transforming Growth Factor b receptors in Verrucous and Squamous Cell Carcinoma. Arch Otolaryngol Head Neck Surg 1999;125:849-54.
[28] Saito T, Nakajima T, Mogi K. Immunohistochemical Analysis of Cell Cycle-associated Proteins p16, pRb, p53, p27 and Ki-67 in oral Cancer and Precancer with Special Reference to Verrucous Carcinomas. J Oral Pathol Med 1999;28:226-32.
[29] Impola U, Uitto VJ, Hietanen J, Hakkinen L, Zhang L, Publisher’s note Whioce Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Larjava H, et al. Differential Expression of Matrilysin-1 (MMP-7), 92 kD Gelatinase (MMP-9), and Metalloelastase (MMP-12) in Oral Verrucous and Squamous Cell Cancer. J Pathol 2004;202:14-22.
[30] Kamat M, Rai BD, Puranik RS, Datar UV. AComprehensive Review of Surgical Margins in Oral Squamous Cell Carcinoma Highlighting the Significance of Tumor-free Surgical Margins. J Cancer Res Ther 2019;15:449-54.